Combination therapy with immune-cell therapy and immune check point inhibitor

A clinical trial on the efficacy of combination therapy with immune-cell therapy(Alpha beta T-cell therapy) and immune check point inhibitor for malignant tumor - Combination therapy with immune-cell therapy and immune check point inhibitor

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTc031190101

Enrollment

Registered

2019-09-19

Start date

2020-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

blood collection for cell culture and tests. combination of of immune cell administrations and immune checkpoint inhibitor infusion, total 4 times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A patient MUST: 1) Be diagnosed with relapsed or advanced malignant tumor. 2) Have a measurable lesion of tumor. 3) Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1. 4) Be administered immune check point inhibitor and immune-cell therapy within 4 weeks at the clinic. 5) Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed. 6) Provide agreement of the attending doctor to participate in this study. 7) Have a backup hospital in the case of emergency. 8) Provide written consent to participate in this study.

Exclusion criteria

Exclusion criteria: A patient MUST NOT: 1) Have a positive result of HIV antibody. 2) Have a T cell-, NK cell-derived malingnant lymphoma/leukemia (in the case of activated immune-cell therapy). 3) Be post allogenic bone marrow transplantation. 4) Have a history of a serious adverse event due to immune check point inhibitor. 5) Be a female who is pregnant, lactating, or with a possibility of pregnancy. 6) A patient who is judged as inadequate for enrolment by doctors is excluded

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
Safety, Immunological response	—

Countries

Japan

Contacts

Public ContactEri Oguma

Koshikai, Non-profit Medical Corporation

citeg@j-immunother.com+81-3-5244-5751

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026